Clinical Research on Albumin-Bound Paclitaxel-Based Chemotherapy for Advanced Esophageal Cancer

Yuan, Yuan; Zhang, Yan; Shi, Lin; Mei, Jing-Feng; Feng, Jif-Eng; Shen, Bo

추천

검색

자료유형: 학술저널

저자정보: Yuan, Yuan (Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute) Zhang, Yan (Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute) Shi, Lin (Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute) Mei, Jing-Feng (Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute) Feng, Jif-Eng (Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute) Shen, Bo (Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제12호

발행연도: 2015.1

수록면: 4,993 - 4,996 (4page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: To evaluate the efficacy and safety of albumin-bound paclitaxel-based chemotherapy in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy. Materials and Methods: We collected29 advanced esophageal cancer patients who received albumin-bound paclitaxel-based chemotherapy fromJune 2009 to September 2013, and the efficacy and safety of the compound were evaluated. These patients were treated with $100-150mg/m^2$ nab-paclitaxel on days 1,8. The cycle was repeated every 3 weeks. Clinical efficacy was evaluated every two cycles. Results: Of the 29 patients, two persons interrupted treatment because of adverse reactions, failed to evaluate efficacy effect. The rest of 27 patients who could be evaluated for short-term response, 10 patients (37%) achieved partial response, 2 (7.4%) remained stable disease, and 15 (55.6%) had progressivedisease. The objective response rate was 37%, and the disease control rate was 44.4%.The median time to progression was 6.6 months.The major adverse reactions includedalopecia (62.07%), neutropenia (65.5%), gastrointestinalreaction (10.3%) andsensory neuropathy(6.8%). Conclusions: The albumin-bound paclitaxel-based chemotherapy is efficacy and safety in treatment for patients with advanced esophageal cancer who failed in first-line chemotherapy.

#Albumin-bound paclitaxel #advanced esophageal cancer #chemotherapy

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!